Yes it's good to temper expectations a bit, only 65% of Americans have health insurance so the potential market is more like double the size of Japan not triple.
Also I recall a video of Matt or Howie saying that they think the insurance companies would likely only pay $540 so Bot will probably only charge $540 so there's no gap payment for consumers.
Another concern is the delay from the relabeling will have allowed people to try qbrexa and more than 40% of them will have experienced zero side effects so they are unlikely to change products if they are having success with the competition.
That said at $6000 per year per person 50,000 patients will bring in 300million $ so there is still amazing possibility for huge profits here. Aimo
Yes it's good to temper expectations a bit, only 65% of...
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
27.5¢ |
Change
-0.005(1.79%) |
Mkt cap ! $433.1M | |||
| Open | High | Low | Value | Volume |
| 28.5¢ | 29.0¢ | 27.0¢ | $1.828M | 6.618M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 1238357 | 27.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 27.5¢ | 31084 | 1 |
View Market Depth
| Last trade - 16.10pm 10/05/2024 (20 minute delay) ? |
|
|||||
|
Last
27.5¢ |
Change
-0.005 ( 3.51 %) |
||||
| Open | High | Low | Volume | ||
| 28.5¢ | 29.0¢ | 27.0¢ | 3100791 | ||
| Last updated 15.59pm 10/05/2024 ? | |||||
| BOT (ASX) Chart |